Revenue
$9.86B
Gross Margin
+69.8%
Operating Margin
+15.6%
Net Margin
+13.9%
Income statement waterfall for Biogen (BIIB) — TTM through Q1 2026
Net income: $1.37B
Margin breakdown for Biogen (BIIB) — TTM through Q1 2026
| Line item | Amount | Running total |
|---|---|---|
| Revenue | $9.86B | $9.86B |
| Cost of Revenue | −$2.98B | $6.88B |
| Gross Profit | $6.88B | $6.88B |
| Operating Expenses | −$5.33B | $1.54B |
| Operating Income | $1.54B | $1.54B |
| Other Income / Expense | −$74.30M | $1.47B |
| Pre-tax Income | $1.47B | $1.47B |
| Income Tax | −$95.61M | $1.37B |
| Net Income | $1.37B | $1.37B |
- Revenue$9.86B
- Cost of Revenue−$2.98B
- Gross Profit$6.88B
- Operating Expenses−$5.33B
- Operating Income$1.54B
- Other Income / Expense−$74.30M
- Pre-tax Income$1.47B
- Income Tax−$95.61M
- Net Income$1.37B
Want to see what changed vs last year?Profit Bridge
Frequently asked questions
Data & methodology
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Income Statement
Balance Sheet
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation
Overview
Income Statement